Hennion & Walsh Asset Management Inc. Increases Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Hennion & Walsh Asset Management Inc. boosted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 17.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 77,610 shares of the specialty pharmaceutical company's stock after purchasing an additional 11,304 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.14% of Supernus Pharmaceuticals worth $2,542,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Vident Advisory LLC raised its stake in Supernus Pharmaceuticals by 2.2% during the fourth quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company's stock worth $520,000 after purchasing an additional 309 shares during the period. Summit Investment Advisors Inc. raised its stake in Supernus Pharmaceuticals by 7.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company's stock worth $190,000 after purchasing an additional 369 shares during the period. Bank of Montreal Can raised its stake in Supernus Pharmaceuticals by 6.6% during the fourth quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company's stock worth $275,000 after purchasing an additional 473 shares during the period. HighTower Advisors LLC grew its stake in Supernus Pharmaceuticals by 7.3% during the fourth quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company's stock worth $330,000 after buying an additional 624 shares during the period. Finally, Raiffeisen Bank International AG acquired a new stake in shares of Supernus Pharmaceuticals in the fourth quarter worth $25,000.

Analysts Set New Price Targets

Several research firms have recently issued reports on SUPN. Cantor Fitzgerald reissued a "neutral" rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, May 16th.

Supernus Pharmaceuticals Stock Up 2.5%

Shares of Supernus Pharmaceuticals stock traded up $0.81 during trading hours on Friday, hitting $33.15. The company's stock had a trading volume of 354,750 shares, compared to its average volume of 478,015. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28. The business has a fifty day moving average of $31.95 and a 200 day moving average of $34.45. The company has a market capitalization of $1.86 billion, a PE ratio of 30.98 and a beta of 0.71.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.